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Abstract
Background: We hypothesized that hippocampal-sparing radiotherapy via volumetric modulated arc therapy (VMAT)
could preserve the neurocognitive function (NCF) of patients with primary brain tumors treated with radiotherapy.
Methods: We reviewed data from patients with primary brain tumors who underwent hippocampal-sparing brain
radiotherapy via VMAT between February 2014 and December 2015. The optimization criteria for the contralateral
hippocampus was a maximum dose (Dmax) of less than 17 Gy. For NCF evaluations, the Seoul Verbal Learning Test for
total recall, delayed recall, and recognition (SVLT-TR, DR, and Recognition) was performed at baseline and at seven
months after radiotherapy.
Results: A total of 26 patients underwent NCF testing seven months after radiotherapy. Their median age was 49.5 years
(range 26–77 years), and 14 (53.8%) had grade III/IV tumors. The median Dmax to the contralateral hippocampus
was 16.4 Gy (range 3.5-63.4). The median mean dose to the contralateral hippocampus, expressed as equivalent to a
2-Gy dose (EQD2/2), was 7.4 Gy2 (0.7–13.1). The mean relative changes in SVLT-TR, SVLT-DR, and SVLT-Recognition at
seven months compared to the baseline were − 7.7% (95% confidence interval [CI], − 19.6% to 4.2%), − 9.2% (95% CI,
− 25.4% to 7.0%), and − 3.4% (− 12.7% to 5.8%), respectively. Two patients (7.7%) showed deteriorated NCF in the
SVLT-TR and SVLT-DR, and three (11.5%) in the SVLT-Recognition. The mean dose of the left hippocampus and bilateral
hippocampi were significantly higher in patients showing deterioration of the SVLT-TR and SVLT-Recognition than in
those without deterioration.
Conclusions: The contralateral hippocampus could be effectively spared in patients with primary brain tumor via
VMAT to preserve the verbal memory function. Further investigation is needed to identify those patients who will
most benefit from hippocampal-sparing radiotherapy of the primary brain tumor.
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Background
Radiotherapy is an integral part of brain cancer treat-
ment. It improves the progression-free survival (PFS) of
patients with low-grade glioma and is also a standard
treatment after surgery with or without chemotherapy in
cases of high-grade glioma.
While the tumor itself may affect the neurocognitive
function (NCF) of patients, radiotherapy is also associated
with declined NCF. In particular, due to the association be-
tween the hippocampal neural stem and memory function,
radiation therapy of the hippocampal area is associated
with deteriorated cognitive and memory functions [1–3].
Effective hippocampal sparing was made possible with
the development of sophisticated radiotherapy delivering
techniques such as intensity modulated radiotherapy
(IMRT) [2, 4, 5]. Hippocampal-sparing whole brain radio-
therapy (WBRT) for brain metastases was proven to be
effective in a recent clinical trial. The Radiation Therapy
Oncology Group (RTOG) 0933 trial enrolled 113 patients
with brain metastases treated with hippocampal-sparing
WBRT, showing promising results in the preservation of
memory function, compared to historical data [6].
However, unlike WBRT, the hippocampal-sparing strategy
for the radiotherapy treatment of primary brain tumor has
not been thoroughly evaluated. Although the dosimetric
feasibility has been reported in a number studies [2, 7–17],
to our knowledge, there has been no report on the associ-
ation between NCF and hippocampal-sparing radiotherapy.
Therefore, we report a dosimetric profile of hippocampal-
sparing radiotherapy for the treatment of primary brain
tumor as well as the change in NCF of the patients.
Methods
Patient Selection
Hippocampal-sparing radiotherapy to the brain was
delivered using the volumetric modulated arc therapy
(VMAT) technique between February 2014 and December
2015 at Seoul National University Bundang Hospital. A
total of 74 patients have received partial brain irradiation
for primary brain tumor, 69 of whom agreed to undergo
NCF testing at baseline. Among them, 26 patients also
underwent NCF testing 7 months after radiotherapy. After
obtaining approval from the Institutional Review Board
(No. B-1411/276-105), we analyzed the medical records
and dosimetric parameters of these patients.
Radiotherapy Simulation
All patients were positioned using a Variable Axis
Baseplate ™ (CIVCO Medical Instruments, Kalona, IA,
USA). The head was inclined as previously described [18].
The computed tomography (CT) scans were acquired by
using a Brilliance CT Big Bore™ CT simulator (Philips,
Cleveland, OH, USA) with a slice thickness of 2 mm.
VMAT Plan Technique
All CT images of the patients were fused with their
recent magnetic resonance (MR) images. The hippocampus
was delineated according to RTOG guidelines [19]. All
contours were delineated by the same radiation oncologist
(I.A.K) and each delineation was peer-reviewed by K.S.K
and J.Y.S. An optimization criterion for the hippocampus
was a maximum dose (Dmax) of less than 17 Gy. However,
we did not compromise the coverage of the planning target
volume (PTV). In cases where the ipsilateral hippocampus
was close to the PTV, we tried to meet the dosimetric
criteria for the contralateral hippocampus. The brain stem,
optic chiasm, and optic apparatus were also delineated.
The other organs at risk were prioritized over the
hippocampal dose constraint.
For primary brain tumors, the clinical target volume
(CTV) was calculated with an adequate margin of 1.5 –
2.0 cm from the tumor bed or gross tumor. The prescrip-
tion dose was 60 Gy to the PTV for high-grade glioma
and 40 – 56 Gy for low-grade glioma. The mean dose
(Dmean) hippocampus was calculated as equivalent to a
2-Gy dose (EQD2/2) with α/β = 2.
NCF
NCF was assessed using the Mini-Mental State Examination
(MMSE); Seoul Verbal Learning Test (SVLT); and Rey
Complex Figure Test, and Recognition Trial (RCFT)
[20–23]. The SVLT is used to assess the verbal memory
system using a list of 12 nouns with four words drawn
from each of three semantic categories. The total recall
(SVLT-TR) trial is the sum of the three learning trials.
The SVLT also includes a 20-min delayed recall trial
(SVLT-DR) and a yes/no delayed recognition trial (SVLT-
Recognition). This last trial consists of a randomized list
of 12 target words and 12 non-target words, six of which
are drawn from the same categories as those of the targets.
This study was standardized and norms that have been
adjusted for age, education, and gender were devel-
oped for the elderly Korean population [22]. The NCF
test was conducted at baseline and 7 months after
radiotherapy. The relative differences were measured
as ΔNCF = (NCFB-NCFF)/NCFB, where B = baseline, F =
follow-up, and the deterioration in the NCF test from
baseline was defined as a z-score drop of 1.5 (drop of 1.5
standard deviations).
Statistical analysis
The doses administered to the bilateral hippocampi and
right and left hippocampus of the two groups were com-
pared using Student’s t-tests. P-values less than 0.05 were
considered to indicate statistically significant differences.
Analyses were performed using PASW Statistics for
Windows, Version 18.0 (SPSS Inc., Chicago, IL).
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Results
Patients’ Characteristics
Of the 69 patients who agreed to undergo NCF testing at
baseline, 26 also underwent the test 7 months after radio-
therapy. Their median age was 49.5 years (range 26-77 years)
and 57.7% of the patients were female. Twelve patients
(46.2%) had WHO grade I or II tumor, whereas 14 patients
(53.8%) had grade III or IV tumor. The median PTV volume
was 173.1 cm3 (range 30.3-493.6) and the median prescribed
dose was 60 Gy (range 40-60). Concurrent chemotherapy
was administered to eight patients (30.8%) diagnosed with
glioblastoma (Table 1).
Dosimetric Analysis
The median doses to 100% of the structure (D100%) and
Dmax of the contralateral hippocampus were 7.2 Gy
(range 0.6–11.7) and 16.4 Gy (range 3.5–63.4), respectively.
The median Dmean expressed in EQD2/2 to the contralateral
hippocampus was 7.4 Gy2 (range 0.7–13.1). The ipsilateral
hippocampus received a higher dose. In addition, the
median Dmax and Dmean (EQD2/2) of the ipsilateral
hippocampus were 40.9 Gy (range 5.7–64.3) and 10.3 Gy2
(range 1.0–62.3), respectively. The median values of the
maximal doses to the brain stem and optic chiasm were
43.3 Gy (range 0.2–61.5) and 42.5 Gy (range 1.0–57.8),
respectively. The other organs at risk could be effectively
spared (Table 2).
NCF Test Results
Of the 26 patients who underwent neurocognitive testing
at 7 months, two patients diagnosed with gliosarcoma and
glioblastoma had progressive disease before 7 months.
The other 24 patients presented with stable disease at 7
months. At the median follow-up of 13.9 months (range
7.0–25.6), the median PFS and overall survival were not
reached. At the last follow-up, eight patients had progressed
and one patient had died.
The NCF test results at baseline and at 7 months for
the 26 patients are listed in Table 3 and Fig. 1. The mean
relative change of SVLT-TR, SVLT-DR, and SVLT-
Recognition at 7 months compared to the baseline were
− 7.7% (95% confidence interval [CI], − 19.6% to 4.2%),
− 9.2% (95% CI, − 25.4% to 7.0%, after excluding one
patient with 0 at baseline), and − 3.4% (− 12.7% to
5.8%), respectively. The patients with deterioration in
the tests included two (7.7%) in the SVLT-TR and
SVLT-DR and three (11.5%) in the SVLT-Recognition. In
regard to the RCFT, 24%, 8%, 8%, and 12% of the patients
showed deterioration, respectively.
Hippocampal Dose and Neurocognitive Impairment
We compared the hippocampal dose of the patients with
varying NCF test results (Table 4 and Additional file 1:
Table S1). We compared the right, left, contralateral,
ipsilateral, and bilateral hippocampi mean doses (EQD2/2),
respectively. The mean doses of the left hippocampus and
bilateral hippocampi were significantly higher in patients
with deterioration of SVLT-TR and SVLT-Recognition than
in those without deterioration. The bilateral hippocampal
Table 1 Patients’ and tumor characteristics
Number Percent
























Bx only/No surgery 4 15.4










Planning Target Volume (PTV)
Vol(cc) 173.1 cm3 (30.3-493.6)
Prescribed dose 60 Gy (40-60)
GTR gross total resection; STR, subtotal resection
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mean dose was significantly higher in patients with
impaired RCFT-Recognition test results (p = 0.042).
Discussion
Numerous studies have assessed the association between
the radiation dose to the hippocampus and memory
function in patients [24, 25]. Furthermore, the NCF decline
in patients treated with WBRT is associated with the
hippocampal radiation dose [26, 27]. The recent develop-
ment of radiotherapy techniques has made hippocampal-
sparing radiotherapy possible, which was shown to be
efficient in the WBRT in a recent clinical trial [6].
However, there are several considerations when applying
the hippocampal-sparing strategy to primary brain tumors.
First, compromising the target volume for hippocampal-
sparing is not recommended. When treating brain metas-
tases, hippocampal-sparing WBRT has an acceptable risk.
Ghia et al. reviewed 100 patients with brain metastasis,
reporting that 8% had metastases within 5 mm of the
hippocampus [28]. The modest increase in the risk of
recurrence could be balanced with salvage stereotactic
radiosurgery. However, in primary brain tumor, the
safety of compromising the target volume for the
hippocampus has not been validated. In high-grade
glioma, recurrences are most often located within 2 cm
of the original tumor [29]. Moreover, the report that
patients with glioblastoma involving the subventricular
zone have decreased overall survival and PFS remains
controversial [30, 31]. The recently published American
Society for Radiation Oncology (ASTRO) guidelines for
glioblastoma noted that given the absence of published
data for the hippocampal-sparing in glioblastoma patients,
the panel does not recommend compromising the target
coverage for hippocampus protection [32].
Second, the hippocampi have a bilateral structure. In
case the ipsilateral hippocampus is close to the target
volume, we could at least spare the contralateral hippo-
campus by using the IMRT technique [8]. However, it is
uncertain if this strategy could be beneficial for the pres-
ervation of the memory function. Lesion studies indicate
that the left and right temporomesial structures are
essential for verbal and visuospatial memory, respect-
ively [33, 34]. Patients with left lobe-origin complex
partial seizures have abnormalities in verbal memory
[35], while those with nondominant foci may have defi-
cits in visuospatial memory, even though this is less
established [34]. Jalali et al. reported that radiotherapy
doses to the left temporal lobe are predictors of neuro-
cognitive decline [24]. In the current study, we could
spare the contralateral hippocampus to the median value
of Dmean (EQD2/2) to 7.4 Gy2. Moreover, the left hippo-
campal dose was significantly associated with SVLT,
Table 2 Dosimetric analysis
Dosimetric parameters Median (range)
Hippocampus
Contralateral
Vol(cc) 1.8 cm3 (0.9-2.4)
D100% 7.2Gy (0.6-11.7)
Dmax 16.4 Gy (3.5-63.4)
Dmean 12.3 Gy (1.3-19.7)
Dmean (EQD2/2) 7.4 Gy2 (0.7-13.1)
Ipsilateral
Vol(cc) 1.7 cm3 (0.6-2.3)
D100% 8.4 Gy (0.7-60.0)
Dmax 40.9 Gy (5.7-64.3)
Dmean 15.9 Gy (2.0-60.3)
Dmean (EQD2/2) 10.3 Gy2 (1.0-63.4)
Bilateral
Dmean 13.4 (1.8-38.3)
Dmean (EQD2/2) 8.3 Gy2 (0.9-31.3)
Optic nerve
Dmax 31.7 Gy (0.5-58.5)
Optic chiasm
Dmax 42.5 Gy (1.0-57.8)
Brain stem





D100% dose to 100% volume of the structure, Dmax maximum dose, Dmean
mean dose, EQD2/2 equivalent 2 Gy dose with α/β = 2




95% CI Probability of
deteriorationb(%)
MMSE − 1.2 − 9.8 to 7.4 3.8
SVLT-Total recall −7.7 −19.6 to 4.2 7.7
SVLT-Delayed recall −9.2c − 25.4 to 7.0c 7.7
SVLT-Recognition −3.4 −12.7 to 5.8 11.5
RCFT-COPY 1.8 −7.4 to 11.1 24
RCFT-Immediate
recall
−8.1 −36.2 to 20.0 8
RCFT-Delayed recall −25.2d − 52.8 to 2.5d 8
RCFT-Recognition −3.8 −11.2 to 4.0 12
MMSE Mini-Mental State Examination, SVLT Seoul Verbal Learning Test, RCFT Rey
Complex Figure Test and Recognition Trial
aΔNCF = (NCFB-NCFF)/NCFB, Where B = baseline and F = follow-up, (Minus change
indicate improved NCF)
bDeterioration in NCF test from baseline defined as drop of z-score 1.5 (drop
of 1.5 standard deviation)
cExclusion of one patient with 0 test result at baseline
dExclusion of one patient who could not be assessed at baseline
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Fig. 1 Mini-Mental State Examination (MMSE) and Seoul Verbal Learning Test (SVLT) score at baseline and at seven months
Table 4 Association between hippocampus dose and neurocognitive test deterioration
Mean dose (EQD2/2)
Bilateral hippocampi P value Right hippocampus P value Left hippocampus P value
SVLT-Total recall 0.033a 0.398 0.013a
No Deterioration (n = 23) 10.6 ± 6.5 15.7 ± 16.8 11.8 ± 14.1
Deterioration (n = 3) 20.3 ± 11.5 7.2 ± 1.7 37.7 ± 27.6
SVLT-Delayed recall 0.115 0.558 0.074
No Deterioration (n = 24) 11.0 ± 6.7 15.2 ± 16.6 13.1 ± 15.0
Deterioration (n = 2) 19.8 ± 16.3 8.2 ± 0.1 36.0 ± 38.9
SVLT-Recognition 0.003a 0.427 0.001a
No Deterioration (n = 23) 10.2 ± 6.0 13.8 ± 15.8 11.1 ± 11.7
Deterioration (n = 3) 23.3 ± 9.4 21.8 ± 19.5 43.1 ± 30.9
RCFT-COPY 0.469 0.211 0.261
No Deterioration (n = 20) 11.1 ± 6.6 16.9 ± 17.7 12.7 ± 14.9
Deterioration (n = 6) 13.7 ± 10.7 7.5 ± 3.7 22.0 ± 24.6
RCFT-Immediate recall 0.156 0.513 0.081
No Deterioration (n = 24) 11.1 ± 6.6 15.3 ± 16.5 13.1 ± 15.0
Deterioration (n = 2) 19.0 ± 17.4 7.4 ± 1.2 36.0 ± 39.4
RCFT-Delayed recall 0.156 0.513 0.081
No Deterioration (n = 24) 11.1 ± 6.6 15.3 ± 16.5 13.1 ± 15.0
Deterioration (n = 2) 19.0 ± 17.4 7.4 ± 1.2 35.6 ± 39.4
RCFT-Recognition 0.042a 0.406 0.257
No Deterioration (n = 23) 10.6 ± 6.5 13.8 ± 16.0 13.4 ± 15.2
Deterioration (n = 3) 19.9 ± 11.5 22.1 ± 20.9 25.8 ± 32.7
Numbers are represented as mean ± SD
SVLT Seoul Verbal Learning Test, RCFT Rey Complex Figure Test and Recognition Trial
aindicate statistical significance by student’s t-test
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whereas the right hippocampal dose was not. In regard
to the preservation of the verbal memory function, spar-
ing the contralateral hippocampus with the right lobe
lesion could be effective. In the current study, the pa-
tients had undergone RCFT, which evaluates visuospatial
memory. However, we did not observe an association
between the deterioration of RCFT results and the radi-
ation dose to the right hippocampus. Further investigation
to identify the association between the visuospatial
memory function impairment and the radiation dose to
the right hippocampus is required.
Third, unlike the WBRT, the target region differs among
patients undergoing radiotherapy of the primary brain
tumor. Therefore, comparisons of the hippocampal dosi-
metric profile and NCF toxicity are difficult. Several stud-
ies reported consistent results with those of our study
regarding the dosimetric profile of the hippocampus when
applying the hippocampal-sparing strategy using various
IMRT techniques for the radiotherapy of the primary
brain tumor [2, 7–17]. Pinkham et al. reported the dosi-
metric feasibility of hippocampal-sparing IMRT in grade
II and grade III gliomas. They reported a median mean
dose to the contralateral hippocampus of 24.9 Gy (range
5.1–58 Gy) [9]. Marsh and colleagues achieved mean
doses of 15.8 Gy and 12 Gy for patients with high-
grade and low-grade gliomas, respectively [13]. In re-
gard to other critical structures, we achieved acceptable
radiation doses for all vital organs.
The memory function deterioration is reportedly 30%–
60% eight to 18 months after cranial irradiation for
primary brain tumor [36–39]. In the RTOG 0933 trial, the
probability of deterioration of the Hopkins Verbal Learn-
ing Test-Revised Delayed Recall score of patients who
underwent hippocampal sparing radiotherapy was 17.2%
at 6 months [6]. In the current study, the deterioration in
the SVLT-DR test was 7.7%. However, direct comparison
of this result with those of other studies has limitations.
We only analyzed patients who underwent neurocognitive
function tests at 7 months; the compliance with this test
at 7 months was 38%, whereas the compliance of the NCF
test at 6 months in the RTOG 0933 trial was 54%. Second,
this study included patients with heterogeneous histology.
Rapid progression of WHO IV disease might affect the
neurocognitive function test. Of the two patients who
progressed before the NCF test at 7 months, one patient
with a left hippocampus dose as high as 63.4 Gy EQD2/2
exhibited an NCF test decline. Meanwhile, in patients with
less aggressive histology, hippocampus-sparing radiotherapy
may be more beneficial. However, the association between
the integral dose to normal brain tissue and long-term
neurocognitive changes should be carefully investigated in
low-grade tumors especially in young patients. Further
prospective studies with homogenous disease would clarify
the benefit of hippocampal-sparing partial brain irradiation.
Conclusion
We used VMAT to apply hippocampal-sparing radio-
therapy to primary brain tumors. The hippocampus
could be reasonably spared and NCF tests performed 7
months after radiotherapy showed promising results in
the preservation of verbal memory function. The left
hippocampal mean dose was associated with the deterior-
ation of the memory function, while the right hippocampal
mean dose was not. Further investigation is needed in
order to select patients who will most benefit from
hippocampal-sparing radiotherapy of the primary brain
tumor.
Additional file
Additional file 1: Table S1. Association between hippocampus dose
and neurocognitive test deterioration. (DOCX 20 kb)
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